Prasad S. Kulkarni

ORCID: 0000-0003-3625-9236
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • SARS-CoV-2 and COVID-19 Research
  • Bacterial Infections and Vaccines
  • Inflammatory mediators and NSAID effects
  • Virology and Viral Diseases
  • Vaccine Coverage and Hesitancy
  • Pneumonia and Respiratory Infections
  • Eicosanoids and Hypertension Pharmacology
  • Influenza Virus Research Studies
  • Viral gastroenteritis research and epidemiology
  • Glaucoma and retinal disorders
  • Hepatitis B Virus Studies
  • Rabies epidemiology and control
  • Nitric Oxide and Endothelin Effects
  • Viral Infections and Immunology Research
  • Animal Virus Infections Studies
  • Respiratory viral infections research
  • COVID-19 Clinical Research Studies
  • Viral Infections and Outbreaks Research
  • Hepatitis C virus research
  • Ocular Surface and Contact Lens
  • Hydrological Forecasting Using AI
  • Ocular Diseases and Behçet’s Syndrome
  • Corneal Surgery and Treatments
  • Streptococcal Infections and Treatments
  • Malaria Research and Control

Serum Institute of India (India)
2016-2025

University of Agricultural Sciences Raichur
2018-2025

Dr. D. Y. Patil Medical College, Hospital and Research Centre
2025

Veterinary Biological and Research Institute
2007-2024

Institute of Medical Sciences
2023

Dr. Babasaheb Ambedkar Marathwada University
2023

Banaras Hindu University
2023

Syngene International (India)
2022

University of Mumbai
2022

B.J. Medical College
2021

Raches Ella Siddarth Reddy William C. Blackwelder Varsha Potdar Pragya D. Yadav and 95 more Vamshi Sarangi Sanjay Kumar Suman Kanungo Sanjay Rai Prabhakar Reddy Savita Verma Chandramani Singh Sagar Vivek Redkar Satyajit Mohapatra Anil Kumar Pandey Pajanivel Ranganadin Raghvendra Gumashta Manish Multani Shameem Mohammad Parul Bhatt Laxmi Kumari Gajanan Sapkal Nivedita Gupta Priya Abraham Samiran Panda Sai Prasad Balram Bhargava Krishna M. Ella Krishna Mohan Vadrevu Pradeep Aggarwal V. Aglawe Abdullhameed May Ali Nitin Anand N. Awad Varun Bafna G. Balasubramaniyam Archana Bandkar P Basha V. Bharge Amit Bhate Sameer Bhate V. Bhavani Ramesh Bhosale DV Chalapathy C. Chaubal Deepak Chaudhary Arun B. Chavan Parth Desai Dinesh Dhodi Siddhartha Dutta Rakesh Garg Kapil Garg Melvin George Pankaj Goyal Randeep Guleria Sneh Lata Gupta Mansi Jain Mansi Jain Sonal Jindal Manju Kalra Shashi Kant Pooja Khosla Prasad S. Kulkarni Pradeep Kumar Y Kumar A. S. Majumdar PritiLokesh Meshram Vaibhav Mishra Satyajit Mohanty Julie McCulloh Nair Shivam Pandey Samir Kumar x Dr. Samir Kumar Panigrahi Bapugouda Sahebagouda Patil Vrunda More Patil Prashant Rahate Vino S. Raj Sunita Ramanand Kiran Rami Balaji Ramraj S. Rane Venkatarao Epari N. Mallikarjuna Rao R. Raphael Goutham Reddy Vivek Redkar Sagar Vivek Redkar Ashutosh Sachdeva Jayanta Saha Jyotiranjan Sahoo Prakash Sampath A. Savith Mihir Shah S. Lokesh Rajeev Sharma Priyanka Sharma Deepak Sharma Akhil Kant Singh Jasdeep Singh Prateek Singh S. Sivaprakasam

10.1016/s0140-6736(21)02000-6 article EN other-oa The Lancet 2021-11-11
Mehreen S. Datoo Alassane Dicko Halidou Tinto Jean‐Bosco Ouédraogo Mainga Hamaluba and 95 more Ally Olotu Emma Beaumont Fernando Ramos Lopez Hamtandi Magloire Natama Sophie Weston Mwajuma Chemba Yves Daniel Compaoré Djibrilla Issiaka Diallo Salou Anyirékun Fabrice Somé Sharon Omenda Alison M. Lawrie Philip Bejon Harish Rao Daniel Chandramohan Rachel Roberts Sandesh Bharati Lisa Stockdale Sunil Gairola Brian Greenwood Katie Ewer John Bradley Prasad S. Kulkarni Umesh Shaligram Adrian V. S. Hill Almahamoudou Mahamar Koualy Sanogo Youssoufa Sidibé Kalifa Diarra Mamoudou Samassekou Oumar Attaher Amadou Tapily Makonon Diallo Oumar M Dicko Mahamadou Kaya Seydina O Maguiraga Yaya Sankaré Hama Yalcouye Soumaïla Diarra Sidi M. Niambele Ismaila Théra Issaka Sagara Mala Sylla Amagana Dolo Nsajigwa Misidai Sylvester Simando Hania Msami Omary Juma Nicolaus Gutapaka Rose Paul Sarah Mswata Ibrahim Sasamalo Kasmir Johaness Mwantumu Sultan Annastazia Alexander Isaac Kimaro Kauye Lwanga Mwajuma Mtungwe Kassim Khamis Lighton Rugarabam Wilmina F. Kalinga Mohammed Mohammed Janeth Kamange Jubilate Msangi Batuli Mwaijande Ivanny M. Mtaka Matilda Mhapa Tarsis Mlaganile Thabit Mbaga Rakiswendé Serge Yerbanga Wendkouni Samtouma Abdoul Aziz Sienou Zachari Kabré Wendinpui Jedida Muriel Ouedraogo G. Armel Bienvenu Yarbanga Issaka Zongo Hamade Savadogo Joseph Sanon Judicael Compaore Idrissa Kere Ferdinand Lionel Yoni Tewende Martine Sanre Seydou Bienvenu Ouattara Samuel Provstgaard-Morys Danielle Woods Robert W. Snow Amek Nyaguara Caroline Ngetsa Lynette Isabella Ochola‐Oyier Jennifer Musyoki Marianne Munene Noni Mumba Uche J. Adetifa Charles Muiruri Jimmy Shangala Mwawaka

BackgroundRecently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical with seasonal administration in phase 2b trial Burkina Faso. Here, report on safety and of the vaccine 3 enrolling 4800 children across four countries followed for up to 18 months at sites 12 standard sites.MethodsWe did double-blind, randomised, R21/Matrix-M five African differing transmission intensities seasonality. Children (aged 5–36 months) were enrolled randomly assigned (2:1)...

10.1016/s0140-6736(23)02511-4 article EN cc-by-nc The Lancet 2024-02-01

Exogenous prostaglandin (PGE 2 ) contracts bovine and human coronary arteries but its precursor, arachidonic acid, relaxes them. The endoperoxides PGH 3 relax strips, 1 produces contraction. primary prostaglandins exert opposite effects to their own endoperoxide precursors, thus, PGE contract, the arteries. paradoxical dilation produced by arachidonate or suggest that little if any isomerase which converts into exists, a novel, potent, PG-like substance is isolated Although coronaries do not...

10.1126/science.831285 article EN Science 1977-01-28

Group A meningococci are the source of major epidemics meningitis in Africa. An affordable, highly immunogenic meningococcal conjugate vaccine is needed.We conducted two studies Africa to evaluate a new MenA (PsA-TT). In study A, 601 children, 12 23 months age, were randomly assigned receive PsA-TT, quadrivalent polysaccharide reference (PsACWY), or control (Haemophilus influenzae type b [Hib-TT]). Ten later, these children underwent another round randomization within each group full dose...

10.1056/nejmoa1003812 article EN New England Journal of Medicine 2011-06-15

Rotavirus is the most common cause of moderate-to-severe infant diarrhoea in developing countries, resulting enormous morbidity, mortality, and economic burden. A bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV) targeting globally strains was developed India tested a randomized, double-blind, placebo-controlled end-point driven Phase III efficacy clinical trial implemented at six sites across India. Infants 6 to 8 weeks age were randomized (1:1) receive three oral doses BRV-PV...

10.1016/j.vaccine.2017.09.014 article EN cc-by Vaccine 2017-09-26

Background: Developing malaria vaccines has proved difficult with many challenges, including polymorphic antigens, modest field-trial efficacy, and now limitations on vaccine supply preventing widespread impact. RTS,S/AS01, the most effective candidate to date, demonstrated 56% efficacy against uncomplicated clinical over 12 months in a licensure trial African children. Recently, we found that new R21 nanoparticle saponin adjuvant Matrix-M™ showed 75% similar endpoint seasonal administration...

10.2139/ssrn.4584076 preprint EN 2023-01-01

Mumps epidemics in Canada and the United States prompted us to review evidence for effectiveness of 5 different vaccine strains. Early trials with Jeryl Lynn strain demonstrated an efficacy approximately 95%, but epidemic conditions, has been as low 62%; this is still considerably better than another safe strain, Rubini (which close 0% conditions). The Urabe 54%-87% prone cause aseptic meningitis. Little epidemiological information available other vaccines. Leningrad-Zagreb which widely used...

10.1086/520028 article EN Clinical Infectious Diseases 2007-07-25

<b><i>Background and Aims:</i></b> Malnutrition is associated with poor clinical outcomes. Whether there a causal relationship or it merely mirrors severe patient condition remains unclear. We examined the association of malnutrition biomarkers characteristic different pathophysiological states to better understand underlying etiological mechanisms. <b><i>Methods:</i></b> prospectively followed consecutive adult medical inpatients....

10.1159/000444096 article EN Annals of Nutrition and Metabolism 2016-01-01

Aerosolized vaccine can be used as a needle-free method of immunization against measles, disease that remains major cause illness and death. Data on the immunogenicity aerosolized measles in children are inconsistent.We conducted an open-label noninferiority trial involving 9.0 to 11.9 months age India who were eligible receive first dose vaccine. Children randomly assigned single by means either aerosol inhalation or subcutaneous injection. The primary end points seropositivity for...

10.1056/nejmoa1407417 article EN New England Journal of Medicine 2015-04-15

Only a small proportion of blood cultures routinely performed in emergency department (ED) patients is positive. Multiple clinical scores and biomarkers have previously been examined for their ability to predict bacteremia. Conclusive validation these essential. This observational cohort study included with suspected infection who had culture sampling at ED admission. We assessed 5 admission concentrations procalcitonin (PCT), C-reactive protein (CRP), lymphocyte white cell counts, the...

10.1097/md.0000000000002264 article EN cc-by-nc Medicine 2015-12-01

Lack of access to rabies immunoglobulin (RIG) contributes high mortality. A recombinant human monoclonal antibody (SII RMAb) was tested in a postexposure prophylaxis (PEP) regimen comparison with RIG (HRIG)-containing PEP regimen.This phase 2/3, randomized, single-blind, noninferiority study conducted 200 participants World Health Organization category III suspected exposures. Participants received either SII RMAb or HRIG (1:1 ratio) wounds and, if required, intramuscularly on day 0, along 5...

10.1093/cid/cix791 article EN Clinical Infectious Diseases 2017-09-02

We have reported previously that thromboxane A2 (TXA2) and serotonin (5-HT, 5-hydroxytryptamine) are important mediators of cyclic flow variations (CFVs) in a canine model coronary artery stenosis endothelial injury. The present study tested the hypothesis TXA2 receptor antagonist is more effective reducing intracoronary platelet deposition at sites injury severe than 5-HT2 antagonist. CFVs developed after placing plastic constrictor around left anterior descending (LAD) 51 56 dogs....

10.1161/01.cir.78.3.701 article EN Circulation 1988-09-01
Coming Soon ...